10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

NDOR1 Antibody (Center) Blocking Peptide
Synthetic peptide
Catalog # BP17396c

Specification

NDOR1 Antibody (Center) Blocking Peptide - Product Information

Primary Accession Q9UHB4

NDOR1 Antibody (Center) Blocking Peptide - Additional Information

Gene ID 27158

Other Names
NADPH-dependent diflavin oxidoreductase 1 {ECO:0000255|HAMAP-Rule:MF_03178}, 16--{ECO:0000255|HAMAP-Rule:MF_03178}, NADPH-dependent FMN and FAD-containing oxidoreductase {ECO:0000255|HAMAP-Rule:MF_03178}, Novel reductase 1, NDOR1 {ECO:0000255|HAMAP-Rule:MF_03178}, NR1

Format
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

NDOR1 Antibody (Center) Blocking Peptide - Protein Information

Name NDOR1 {ECO:0000255|HAMAP-Rule:MF_03178}

Function
NADPH-dependent reductase which is a central component of the cytosolic iron-sulfur (Fe-S) protein assembly (CIA) machinery (PubMed:10625700, PubMed:28648056, PubMed:23596212, PubMed:20802492, PubMed:15900210). Transfers electrons from NADPH via its FAD and FMN prosthetic groups to the [2Fe-2S] cluster of CIAPIN1, another key component of the CIA machinery (PubMed:28648056, PubMed:23596212, PubMed:20802492). In turn, this reduced cluster provides electrons for assembly of cytosolic iron-sulfur cluster proteins (PubMed:23596212, PubMed:20802492). It can also reduce the [2Fe-2S] cluster of CISD1 and activate this protein implicated in Fe/S cluster

repair (PubMed:28648056). In vitro can fully activate methionine synthase/MTR in the presence of soluble cytochrome b5/CYB5A (PubMed:12871938).

Cellular Location
Cytoplasm, perinuclear region {ECO:0000255|HAMAP- Rule:MF_03178, ECO:0000269|PubMed:10625700, ECO:0000269|PubMed:12871939}. Note=Concentrated in perinuclear structure. {ECO:0000255|HAMAP-Rule:MF_03178, ECO:0000269|PubMed:12871939}

Tissue Location
Low expression in brain, heart, kidney, pancreas, prostate and skeletal muscle. Highest levels in the placenta. Expressed in cancer cell lines including promyelocytic leukemia, HeLaS3, chronic myelagenous leukemia, lymphoblastic leukemia, Burkitt's lymphoma, colorectal adenocarcinoma, lung carcinoma, and melanoma G-361

NDOR1 Antibody (Center) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Blocking Peptides

NDOR1 Antibody (Center) Blocking Peptide - Images

NDOR1 Antibody (Center) Blocking Peptide - Background

This gene encodes an NADPH-dependent diflavin reductasethat contains both flavin mononucleotide (FMN) and flavin adeninedinucleotide (FAD) binding domains. The encoded protein is anenzyme that catalyzes the transfers electrons from NADPH throughFAD and FMN cofactors to potential redox partners. Alternativesplicing results in multiple transcript variants. [provided byRefSeq].

NDOR1 Antibody (Center) Blocking Peptide - References

Kwasnicka-Crawford, D.A., et al. Biochem. Biophys. Res. Commun. 336(2):565-571(2005)Finn, R.D., et al. Pharmacogenet. Genomics 15(6):381-386(2005)Kwasnicka, D.A., et al. J. Biol. Chem. 278(40):39051-39058(2003)Olteanu, H., et al. J. Biol. Chem. 278(40):38310-38314(2003)Finn, R.D., et al. Eur. J. Biochem. 270(6):1164-1175(2003)